- The FDA has granted Fast Track designation to Vor Biopharma's VOR VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML).
- VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33.
- The Company is enrolling in its Phase 1/2a trial for AML patients and remains on track to report initial data in 1H of FY22.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: VOR stock is 4.04% at $16.22 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralacute myeloid leukemiaBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
